Submitted by Anonymous (not verified) on 11 December 2025 - 15:00
Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 18, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 18, Status: Authorised